Amphstar Pharmaceuticals, Inc. Cash Flow Statement
AMPH / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Amphstar Pharmaceuticals, Inc. generated $156M in operating cash flow and $121M in free cash flow in FY2025. Free cash flow margin was 16.8% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M | $1.4M | $48.9M | -$5.7M | $3.6M | $9.8M | -$2.8M | -$10.7M | $11.9M | $18.1M |
| Depreciation & Amortization | - | - | $25.7M | $12.6M | $10.2M | $9.0M | $7.1M | $6.1M | $6.4M | - | - | - | $11.2M | $9.7M |
| Operating Cash Flow | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M | $57.3M | $41.8M | $38.2M | $39.2M | $38.6M | $10.7M | $21.1M | $31.0M | -$1.6M |
| Capital Expenditures | $34.9M | $41.0M | $38.2M | $24.0M | $27.5M | $33.9M | $41.6M | $46.8M | $35.1M | $21.4M | $16.0M | $20.5M | $17.6M | $23.1M |
| Free Cash Flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M | $23.4M | $207.0K | -$8.6M | $4.1M | $17.2M | -$5.3M | $553.0K | $13.4M | -$24.8M |
| Share Buybacks | $75.6M | $85.5M | $58.1M | $39.9M | $28.9M | $24.4M | $22.3M | $25.0M | $30.7M | $9.9M | $9.9M | $345.0K | $199.0K | $811.0K |
| FCF Margin | 16.8% | 23.5% | 22.6% | 13.1% | 16.1% | 6.7% | 0.1% | -2.9% | 1.7% | 6.7% | -2.1% | 0.3% | 5.8% | -12.1% |